{
  "PMC": "5921813",
  "DOI": "10.1111/j.1349-7006.1998.tb00569.x",
  "PMID": "9617337",
  "PMCID": "PMC5921813",
  "title": "Molecular analysis of a Myc antagonist, ROX/Mnt, at 17p13.3 in human lung cancers.",
  "year": 1998,
  "source_url": "https://europepmc.org/article/PMC/PMC5921813",
  "source": "MED",
  "abstract_text": "The chromosome region 17p13 is known to be frequently deleted in lung cancers. We recently showed the presence of an independent, commonly deleted region at 17p13.3, suggesting that in addition to p53 at 17p13.1 an as-yet-unidentified tumor suppressor gene may reside in this telomeric region. Interestingly, the chromosomal location of a recently isolated novel myc antagonist gene, termed ROX/Mnt, coincides exactly with the centromeric border of the commonly deleted region at 17p13.3 in lung cancers. In conjunction with the generally acknowledged roles of myc genes in the pathogenesis of lung cancers, these findings led us to investigate whether ROX/Mnt is altered in lung cancers. Despite an extensive search for alterations in 52 lung cancer specimens. somatic mutations of ROX/Mnt could not be identified. We conclude that ROX/Mnt itself is not a frequent target for 17p13.3 deletions in lung cancers and that further explorations are required to identify the putative tumor suppressor gene at 17p13.3.",
  "full_text": "Jpn J Cancer Res Jpn. J. Cancer Res 10.1111/(ISSN)1349-7006a CAS Japanese Journal of Cancer Research : Gann 0910-5050 1876-4673 Blackwell Publishing Ltd Oxford, UK 5921813 9617337 10.1111/j.1349-7006.1998.tb00569.x CAE347 Article Molecular Analysis of a Myc Antagonist, ROX/Mnt, at 17p13.3 in Human Lung Cancers Takahashi Takao 1 4 Konishi Hiroyuki 1 Kozaki Ken‐ichi 2 Osada Hirotaka 2 Saji Shigetoyo 4 Takahashi Toshitada 3 Takahashi Takashi 1 2 1 Laboratory of Ultrastructure Research, Aichi Cancer Center Research Institute, Kanokoden 1‐1, Chikusa‐ku, Nagoya 464‐8681 2 Pathophysiology Unit, Aichi Cancer Center Research Institute, Kanokoden 1‐1, Chikusa‐ku, Nagoya 464‐8681 3 Laboratory of Immunology, Aichi Cancer Center Research Institute, Kanokoden 1‐1, Chikusa‐ku, Nagoya 464‐8681 4 Department of Surgery II, Gifu University School of Medicine, Tsukasamachi 40, Gifu 500‐8705 * To whom requests for reprints should be addressed at the Laboratory of Ultrastructure Research, Aichi Cancer Center Research Institute. 4 1998 89 4 10.1111/cas.1998.89.issue-4 347 351 (Received December 26, 1997/Revised March 16, 1998/Accepted March 20, 1998) The chromosome region 17p13 is known to be frequently deleted in lung cancers. We recently showed the presence of an independent, commonly deleted region at 17p13.3, suggesting that in addition to p53 at 17p13.1 an as‐yet‐unidentified tumor suppressor gene may reside in this telomeric region. Interestingly, the chromosomal location of a recently isolated novel myc antagonist gene, termed ROX/Mnt, coincides exactly with the centromeric border of the commonly deleted region at 17p13.3 in lung cancers. In conjunction with the generally acknowledged roles of myc genes in the pathogenesis of lung cancers, these findings led us to investigate whether ROX/Mnt is altered in lung cancers. Despite an extensive search for alterations in 52 lung cancer specimens, somatic mutations of ROX/Mnt could not be identified. We conclude that ROX/Mnt itself is not a frequent target for 17p13.3 deletions in lung cancers and that further explorations are required to identify the putative tumor suppressor gene at 17p13.3. ROX Mnt 17p13.3 Lung cancer source-schema-version-number 2.0 cover-date April 1998 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015 REFERENCES 1 ) Minna , J. D. , Sekido , Y. , Fong , K. M. and Gazdar , A. F. Cancer of the lung . In “Cancer Principles & Practice of Oncology ,” ed. DeVita V. T. , Hellman S. and Rosenberg S. A. , pp. 849 – 949 ( 1997 ). Lippincott‐Raven , Philadelphia . 2 ) Kamb , A. , Gruis , N. A. Weaver‐Feldhaus , J. , Liu , Q. , Harshman , K. , Tavtigian , S. V. , Stockert , E. , Day , R. S. , III , Johnson , B. E. and Stolnick , M. H. A cell cycle regulator potentially involved in genesis of many tumor types . Science , 264 , 436 – 440 ( 1994 ). 8153634 3 ) Washimi , O. , Nagatake , M. , Osada , H. , Ueda , R. , Koshikawa , T. , Seki , T. , Takahashi , T. and Takahashi , T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non‐small cell lung cancers . Cancer Res. , 55 , 514 – 517 ( 1995 ). 7834619 4 ) Harbour , J. W. , Lai , S. L. , Whang‐Peng , J. , Gazdar , A. F. , Minna , J. D. and Kaye , F. J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC . Science , 241 , 353 – 357 ( 1988 ). 2838909 5 ) Takahashi , T. , Nau , M. M. , Chiba , I. , Birrer , M. J. , Rosenberg , R. K. , Vinocour , M. , Levitt , M. , Pass , H. , Gazdar , A. F. and Minna , J. D. p53: a frequent target for genetic abnormalities in lung cancer . Science , 246 , 491 – 494 ( 1989 ). 2554494 6 ) Nagatake , M. , Takagi , Y. , Osada , H. , Uchida , K. , Mitsudomi , T. , Saji , S. , Shimokata , K. , Takahashi , T. and Takahashi , T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers . Cancer Res. , 56 , 2718 – 2720 ( 1996 ). 8665501 7 ) Uchida , K. , Nagatake , M. , Osada , H. , Yatabe , Y. , Kondo , M. , Mitsudomi , T. , Masuda , A. , Takahashi , T. and Takahashi T. Somatic in vivo alterations of the JV18‐1 gene at 18q21 in human lung cancers . Cancer Res. , 56 , 5583 – 5585 ( 1996 ). 8971158 8 ) Yokota , J. , Wada , M. , Shimosato , Y. , Terada , M. and Sugimura , T. Loss of heterozygosity on chromosomes 3, 13, and 17 in small‐cell carcinoma and on chromosome 3 in adenocarcinoma of the lung . Proc. Natl. Acad. Sci. USA , 84 , 9252 – 9256 ( 1987 ). 2892196 9 ) Meroni , G. , Reymond , A. , Alcalay , M. , Borsani , G. , Tanigami , A. , Tonlorenzi , R. , Nigro , C. L. , Messali , S. , Zollo , M. , Ledbetter , D. H. , Brent , R. , Ballabio , A. and Carrozzo , R. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a noncanonical E box and acts as a transcriptional repressor . EMBO J. , 16 , 2892 – 2906 ( 1997 ). 9184233 10 ) Hurlin , P. J. , Queva , C. and Eisenman , R. N. Mnt, a novel Max‐interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites . Genes Dev. , 11 , 44 – 58 ( 1997 ). 9000049 11 ) Blackwood , E. M. and Eisenman , R. N. Max: a helix‐loop‐helix zipper protein that forms a sequence‐specific DNA‐binding complex with Myc . Science , 251 , 1211 – 1217 ( 1991 ). 2006410 12 ) Ayer , D. E. , Kretzner , L. and Eisenman , R. N. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity . Cell , 72 , 211 – 222 ( 1993 ). 8425218 13 ) Zervos , A. S. , Gyuris , J. and Brent , R. Mxil, a protein that specifically interacts with Max to bind Myc‐Max recognition sites . Cell , 72 , 223 – 232 ( 1993 ). 8425219 14 ) Hurlin , P. J. , Queva , C. , Koskinen , P. J. , Steingrimsson , E. , Ayer , D. E. , Copeland , N. G. , Jenkins , N. A. and Eisenman , R. N. Mad3 and Mad4: novel Max‐interacting transcriptional repressors that suppress c‐myc dependent transformation and are expressed during neural and epidermal differentiation . EMBO J. , 14 , 5646 – 5659 ( 1995 ). 8521822 15 ) Chen , J. , Willingham , T. , Margraf , L. R. , Schreiber‐Agus , N. , DePinho , R. A. and Nisen , P. D. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells . Nat. Med. , 1 , 638 – 643 ( 1995 ). 7585143 16 ) Eagle , L. R. , Yin , X. , Brothman , A. R. , Williams , B. J. , Atkin , N. B. and Prochownik , E. V. Mutation of the MXI1 gene in prostate cancer . Nat. Genet. , 9 , 249 – 255 ( 1995 ). 7773287 17 ) Carrozzo , R. and Ledbetter , D. H. Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p13.3) . Hum. Mol. Genet. , 2 , 615 ( 1993 ). 18 ) Hibi , K. , Yamakawa , K. , Ueda , R. , Horio , Y. , Murata , Y. , Tamari , M. , Uchida , K. , Takahashi , T. , Nakamura , Y. and Takahashi , T. Aberrant upregulation of a novel integrin α subunit gene at 3p21.3 in small cell lung cancer . Oncogene , 9 , 611 – 619 ( 1994 ). 8290272 19 ) Petersen , S. , Wolf , G. , Bockmühl , U. , Gellert , K. , Dietel , M. and Petersen , I. Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype . Br. J. Cancer , 77 , 270 – 276 ( 1998 ). 9460998 20 ) Hibi , K. , Takahashi , T. , Yamakawa , K. , Ueda , R. , Sekido , Y. , Ariyoshi , Y. , Suyama , M. , Takagi , H. , Nakamura , Y. and Takahashi , T. Three distinct regions involved in 3p deletion in human lung cancer . Oncogene , 7 , 445 – 449 ( 1992 ). 1347916 21 ) Chung , G. T. , Sundaresan , V. , Hasleton , P. , Rudd , R. , Taylor , R. and Rabbitts , P. H. Sequential molecular genetic changes in lung cancer development . Oncogene , 11 , 2591 – 2598 ( 1995 ). 8545116 22 ) Coles , C. , Thompson , A. M. , Elder , P. A. , Cohen , B. B. , Mackenzie , I. M. , Cranston , G. , Chetty , U. , Mackay , J. , Macdonald , M. , Nakamura , Y. , Hoyheim , B. and Steel , C. M. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis . Lancet , 336 , 761 – 763 ( 1990 ). 1976143 23 ) Sato , T. , Tanigami , A. , Yamakawa , K. , Akiyama , F. , Kasumi , F. , Sakamoto , G. and Nakamura , Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer . Cancer Res. , 50 , 7184 – 7189 ( 1990 ). 1977515 24 ) Phillips , N. J. , Ziegler , M. R. , Radford , D. M. , Fair , K. L. , Steinbrueck , T. , Xynos , F. P. and Donis‐Keller , H. Allelic deletion on chromosome 17p13.3 in early ovarian cancer . Cancer Res. , 56 , 606 – 611 ( 1996 ). 8564979 25 ) Biegel , J. A. , Burk , C. D. , Barr , F. G. and Emanuel , B. S. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors . Cancer Res. , 52 , 3391 – 3395 ( 1992 ). 1596898 26 ) Cogen , P. H. , Daneshvar , L. , Metzger , A. K. , Duyk , G. , Edwards , M. S. and Sheffield , V. C. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis . Am. J. Hum. Genet. , 50 , 584 – 589 ( 1992 ). 1347196 27 ) Saxena , A. , Clark , W. C. , Robertson , J. T. , Ikejiri , B. , Oldfield , E. H. and Ali , I. U. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas . Cancer Res. , 52 , 6716 – 6721 ( 1992 ). 1358438 28 ) Fujimori , M. , Tokino , T. , Hino , O. , Kitagawa , T. , Imamura , T. , Okamoto , E. , Mitsunobu , M. , Ishikawa , T. , Nakagama , H. , Harada , H. , Yagura , M. , Matsubara , K. and Nakamura , Y. Allelotype study of primary hepatocellular carcinoma . Cancer Res. , 51 , 89 – 93 ( 1991 ). 1670995 29 ) Park , S. Y. , Kang , Y. S. , Kim , B. G. , Lee , S. H. , Lee , E. D. , Lee , K. H. , Park , K. B. and Lee , J. H. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinomas . Cancer Genet. Cytogenet. , 79 , 74 – 78 ( 1995 ). 7850756",
  "plain_text": "The chromosome region 17p13 is known to be frequently deleted in lung cancers. We recently showed the presence of an independent, commonly deleted region at 17p13.3, suggesting that in addition to p53 at 17p13.1 an as‐yet‐unidentified tumor suppressor gene may reside in this telomeric region. Interestingly, the chromosomal location of a recently isolated novel myc antagonist gene, termed ROX/Mnt, coincides exactly with the centromeric border of the commonly deleted region at 17p13.3 in lung cancers. In conjunction with the generally acknowledged roles of myc genes in the pathogenesis of lung cancers, these findings led us to investigate whether ROX/Mnt is altered in lung cancers. Despite an extensive search for alterations in 52 lung cancer specimens, somatic mutations of ROX/Mnt could not be identified. We conclude that ROX/Mnt itself is not a frequent target for 17p13.3 deletions in lung cancers and that further explorations are required to identify the putative tumor suppressor gene at 17p13.3."
}
